Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Heliox for Neonate With Acute Respiratory Distress Syndrome (ARDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03217149
Recruitment Status : Recruiting
First Posted : July 13, 2017
Last Update Posted : July 13, 2017
Sponsor:
Information provided by (Responsible Party):
Ma Juan, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Brief Summary:
Acute respiratory distress syndrome (ARDS) in neonates has been defined, the role of heliox is not clear.This study aimed to determine whether ARDS neonate would benefit from heliox when oxygenation deteriorated on mechanical ventilation and to identify any potential risk factors related to mortality.

Condition or disease Intervention/treatment Phase
ARDS Drug: heliox combined with MV Drug: MV Not Applicable

Detailed Description:
Acute respiratory distress syndrome (ARDS) can result in severe hypoxemia refractory to mechanical ventilation, mechanical ventilation including high frequency oscillation ventilation is the main method. But it is partial unuseful.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Heliox for Neonate With Acute Respiratory Distress Syndrome (ARDS): A Randomized Controlled Trial
Estimated Study Start Date : September 1, 2017
Estimated Primary Completion Date : August 30, 2020
Estimated Study Completion Date : August 30, 2020


Arm Intervention/treatment
Experimental: heliox combined with mechanical ventilation (MV)
heliox combined with mechanical ventilation (MV) is given to infant with ARDS
Drug: heliox combined with MV
heliox combined with MV is given to infant with ARDS

Active Comparator: mechanical ventilation
mechanical ventilation (MV) is given to infant with ARDS
Drug: MV
MV is given to infant with ARDS




Primary Outcome Measures :
  1. death [ Time Frame: within 100 days ]
    death


Secondary Outcome Measures :
  1. Bayley Scales of Infant Development [ Time Frame: at 2 months old and 2 years old ]
    the survival is assessed by Bayley Scales of Infant Development



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 28 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. infant less than 28 days
  2. diagnosis of ARDS
  3. informed parental consent has been obtained

Exclusion Criteria:

  1. major congenital malformations or complex congenital heart disease
  2. transferred out of the neonatal intensive care unit without treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03217149


Contacts
Layout table for location contacts
Contact: Ma Juan, MD 13883559467 476679422@qq.com
Contact: Ma Juan, MD 1388.559467 476679422@qq.com

Locations
Layout table for location information
China, Chongqing
Department of Pediatrics, Daping Hospital, Third Military Medical University Recruiting
Chongqing, Chongqing, China, 400042
Contact: Juan Ma, physician    18680887330    zoe330@163.com   
Sponsors and Collaborators
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Investigators
Layout table for investigator information
Study Director: Shi Yuan, PhD,MD Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Layout table for additonal information
Responsible Party: Ma Juan, Principal Investigator, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
ClinicalTrials.gov Identifier: NCT03217149     History of Changes
Other Study ID Numbers: heliox for ARDS
First Posted: July 13, 2017    Key Record Dates
Last Update Posted: July 13, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Acute Lung Injury
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury